Is Viking Therapeutics Stock Going to $100?

Viking Therapeutics’ lead obesity candidate VK2735 remains in late-stage development, with maintenance-dosing data expected in Q3 and an oral phase 3 trial targeted for Q4. The stock has fallen to about $27 after peaking above $94 in February 2024, but the average Wall Street target is more than $92 over the next 12 months. The article frames Viking as a speculative biotech with meaningful upside potential if upcoming clinical catalysts are favorable.

Analysis

VKTX remains a classic “data staircase” trade: the next leg is less about current fundamentals and more about whether upcoming readouts de-risk the platform enough to pull in capacity-constrained capital from large-cap obesity winners. The market is still underpricing the optionality of an oral dual agonist, because the strategic value is not just peak sales but sequencing — an oral induction followed by injectable maintenance could widen adherence and broaden payer acceptance, which materially expands addressable duration per patient.

The second-order effect is on the competitive bidding war for obesity mindshare, not just share. If VKTX shows clean maintenance data and a credible path to oral efficacy, it forces incumbents to defend the premium they’ve earned on convenience and tolerability, which could compress enthusiasm for adjacent metabolic names with weaker differentiation. Conversely, any disappointment would likely redirect capital back to the proven leaders, making this a high-beta funnel trade rather than a stable standalone long.

The setup is asymmetric over the next 1-3 quarters: limited downside if the stock is already discounting execution risk, but very large upside if phase 3 initiation and maintenance data reduce the perceived probability of failure. The real tail risk is not clinical efficacy alone; it’s tolerability, dose escalation complexity, and the market’s willingness to capitalize another obesity entrant before commercial infrastructure is proven. That means the stock can rerate violently on protocol details, but also de-rate sharply on any sign that the oral program is more differentiated in presentation than in actual adoption economics.

The consensus seems to be extrapolating peak-market TAM while underweighting the time and capital needed to convert it into revenue. The better lens is that VKTX is a call option on becoming a credible takeout or licensing asset before it becomes a fully funded commercial story. If the next catalysts are positive, the move could be more about strategic scarcity value than discounted cash flow, which is why the stock can overshoot well beyond near-term fair value on incremental de-risking.

Key Decisions for Investors

• Initiate a tactical long VKTX into the next two catalysts (maintenance data and phase 3 initiation) with a 6-12 week horizon; size modestly because the stock should trade like a binary event-driven option, not a core compounding name.
• For relative value, pair long VKTX / short NVO on any strength if the market over-rotates into second-tier obesity optionality; the goal is to isolate rerating on VKTX without taking full obesity beta.
• Buy VKTX call spreads 3-6 months out to capture catalyst convexity while defining downside; structure for a 2-3x premium return if data are merely acceptable, not perfect.
• If VKTX fails to show clean maintenance or oral differentiation, rotate exposure back to the incumbents rather than standing in front of the move; the faster capital-proven winners should reclaim flows immediately.
• Use any post-data spike to trim into strength unless the company demonstrates a clear path to oral/injectable sequencing advantage; the long-term upside is large, but execution risk remains much higher than the market capitalization suggests.